New insider activity at Zomedica ( (ZOMDF) ) has taken place on August 12, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Klass Russell Kevin, the Senior Vice President of Sales at Zomedica, has made a significant investment by purchasing 500,000 shares of Zomedica stock. This transaction is valued at $17,500, showcasing his confidence in the company’s future prospects.
Recent Updates on ZOMDF stock
Zomedica reported a 14% increase in revenue for the second quarter of 2025, driven by strong performance in its diagnostic and therapeutic segments, particularly the TRUFORMA diagnostic platform, which saw an 86% growth in revenue. Despite this, the stock faces mixed financial performance challenges, including persistent profitability issues and a negative P/E ratio, which have impacted its valuation. Analysts have given a Buy rating with a price target of $0.25, citing the company’s strategic initiatives and global expansion plans as positive factors. However, concerns about increased net loss and delisting risks remain, contributing to a Neutral rating from AI Analyst Spark and a Sell technical sentiment signal.
Spark’s Take on ZOMDF Stock
According to Spark, TipRanks’ AI Analyst, ZOMDF is a Neutral.
Zomedica’s stock score reflects mixed financial performance with revenue growth but persistent profitability challenges. The technical analysis shows weak momentum, and the valuation is impacted by a negative P/E ratio. Despite strong earnings call highlights, increased net loss and delisting risks present concerns.
To see Spark’s full report on ZOMDF stock, click here.
More about Zomedica
YTD Price Performance: -72.14%
Average Trading Volume: 1,341,895
Technical Sentiment Signal: Sell
Current Market Cap: $38.36M